Medicaid Bulletin

As NC Medicaid moves forward with its planned implementation of NC Medicaid Managed Care, it is important for enrolled providers to act now to thoroughly review their individual and organization provider enrollment record in NCTracks.

NC Medicaid has received federal approval of additional flexibilities during the COVID-19 pandemic for the NC Innovations Waiver, for individuals with intellectual and developmental disabilities (IDD).

The North Carolina Department of Health and Human Services and North Carolina AHEC are offering two monthly evening webinar series to help prepare providers, practice managers and quality managers engage with NC Medicaid. 

Amended policies will post to the NC Medicaid Clinical Coverage Policies website with an effective date of Oct. 1, 2020. 

Effective with date of service Aug. 13, 2020, the Medicaid and NC Health Choice programs cover tafasitamab-cxix for injection, for intravenous use (Monjuvi®) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.

Strong infection prevention and control practices are critical to reducing the transmission of COVID-19 within long-term care facilities. NC DHHS is reiterating its expectation that providers participate in the infection prevention and control activities. 

This bulletin replaces SPECIAL BULLETIN COVID-19 #119 in its entirety.

The North Carolina Department of Health and Human Services announced the launch of a COVID-19 Exposure Notification app called SlowCOVIDNC. The app will help North Carolinians slow the spread of the virus by alerting them when they may have been exposed to someone who has tested positive for COVID-19.

To begin the preparation for the renewing of the CAP/C waiver, NC Medicaid is soliciting comments, recommendations, and suggestions in the areas of access, flexibilities of home and community-based services, and operational efficiencies. An open public comment period begins Sept. 22, 2020. 

Effective with date of service July 27, 2020, the Medicaid and NC Health Choice programs cover inebilizumab-cdon injection, for intravenous use (Uplizna™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3590 - Unclassified biologics.